Metabolism / Research index
Retatrutide
Retatrutide, also called LY3437943, is investigated for activity at GIP, GLP-1 and glucagon receptors. Triple agonist describes that pharmacology; it does not mean three separate ingredients or establish superiority for every person or outcome. The measured endpoint still determines what a study can support.
Names used in the literature: Retatrutida · Retatrutide · LY3437943
Read the evidence and its sources ↓That presentation is not part of this listing. Review the available options before adding a selection.
Retatrutide 10 mg
- Presentation
- 10 mg
- Catalog reference
- PMX-RETA-10
Retatrutide 20 mg
- Presentation
- 20 mg
- Catalog reference
- PMX-RETA-20
Retatrutide 30 mg
- Presentation
- 30 mg
- Catalog reference
- RETA-30
Availability and documentation await confirmation. Listed quantities identify catalog presentations, not instructions for use.
From molecule to trial
The discovery publication characterized receptor activity and experimental models. It supports identification of the molecule; subsequent clinical results address separate questions about outcomes in people.
Sources: [4]
The phase 2 obesity trial
The randomized 2023 trial enrolled 338 adults with obesity or overweight and a related condition. Retatrutide produced greater weight reduction than placebo: the primary assessment was at 24 weeks, with follow-up and secondary outcomes at 48 weeks. The most frequent adverse events were gastrointestinal, generally mild or moderate. These findings concern the study product, not the catalog vial.
Sources: [1]
Liver fat: a substudy of the same trial
The 2024 paper analyzed 98 participants from the same obesity trial who had metabolic dysfunction-associated steatotic liver disease (MASLD) and baseline liver fat ≥10%. Its primary assessment was relative liver-fat change at 24 weeks, with greater reductions than placebo. This is a substudy of that cohort, not independent replication.
Sources: [2]
Trials and regulatory status
In the FDA information checked on November 8, 2026, retatrutide is not a component of an FDA-approved drug. That statement concerns the United States. Inclusion in a catalog and the existence of clinical trials do not establish authorization of a particular presentation in Mexico or demonstrate its equivalence to trial material.
Sources: [3]
Questions about this reference
Is retatrutide another name for semaglutide?
No. Retatrutide is investigated as a three-receptor agonist. Shared activity at GLP-1 does not make the molecules, results or presentations equivalent. A meaningful comparison requires clearly identified studies and products.
Does less liver fat mean a liver disease is cured?
Not necessarily. A liver-fat measurement is a particular endpoint. It should not become a promise about fibrosis, cirrhosis or other outcomes that the measurement alone does not establish.
Sources and original reading
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
- Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial
- FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
- LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept
Content updated: . How this content is prepared and checked.
Understand before comparing